DR3.3 | Psoriasis Treatment Planning and Counselling — Summary & Reflection

KEY TAKEAWAYS

Devising a treatment plan for psoriasis means matching therapy intensity to disease severity while counselling the patient about a chronic, relapsing, incurable condition. Severity is assessed by BSA (<10% limited, 10–20% moderate, >20% severe), PASI, and DLQI (≥10 indicating significant impairment), with pustular, erythrodermic, and arthritic variants needing systemic or urgent care regardless of area. Limited disease is managed with topical corticosteroids (potency by site), calcipotriol, coal tar, and keratolytics; moderate disease with narrowband UVB phototherapy (preferred, safe in pregnancy) or PUVA; severe disease with systemic methotrexate (folate antagonist; FBC/LFT/renal monitoring; teratogenic), cyclosporine (short-term; nephrotoxic), acitretin (teratogenic; valuable in pustular/erythrodermic disease), or biologics targeting TNF-α/IL-17/IL-23. The cardinal rule is that systemic corticosteroids are contraindicated, as withdrawal precipitates pustular or erythrodermic flares. Counselling — on chronicity, the remission-relapse pattern, adherence, trigger avoidance, monitoring, and psychosocial support — is inseparable from the prescription and is what makes the plan succeed.

REFLECT

Picture yourself explaining a new diagnosis of psoriasis to a young patient who hoped for a cure. What words would you choose to convey that the disease is controllable but lifelong, and how would you prepare them for the relapses that are certain to come? Reflect on the temptation — felt by patients and sometimes by prescribers — to chase the dramatic, rapid clearance that a systemic steroid offers, and on your responsibility to refuse that shortcut while offering something safe in its place. Consider how you would build a plan the patient can actually sustain: realistic goals, an agent suited to their severity and circumstances, a monitoring schedule, and an open door for the psychological toll. How will you make counselling, not just prescribing, a deliberate part of every psoriasis consultation you conduct?